research

Researchers from the National University of Singapore have found a new type of immune cell that could aid in the development of treatments for multiple sclerosis (MS). The study was published on November 21 in the journal Cell Research entitled, “STAT5 programs a distinct subset of GM-CSF-producing T helper…

Researchers in the laboratory of Steve Goldman, MD, PhD, Co-Director of University of Rochester Center for Translational Neuromedicine, are delving deeper into the science behind progressive multifocal leukoencephalopathy (PML), a disease caused by the JC virus, which commonly affects multiple sclerosis patients and others with compromised immune…

The Cognitive Rehabilitation for Attention and Memory trial (CRAMMS), a major study to be conducted on patients suffering from multiple sclerosis, was recently awarded £1,167,000 ($1,828,000) by the British National Health Service (NHS), through its Health Technology Assessment (HTA) Program. The study, which is expected to be the largest trial of its…

The Alliance for Children’s Therapeutics recently announced its plans to broaden its scope of research programs to include several diseases, namely, inflammatory bowel disease (IBD), asthma, and multiple sclerosis (MS) — a progressive, neurodegenerative disease that is estimated to affect 300,000…

In a poster session at the Annual meeting of the Society for Neuroscience in Washington, ENDECE Neural presented pre-clinical results showing their lead drug – NDC-1308 – induces remyelination in mouse models of demyelination disease, such as Multiple Sclerosis. Loss of myelin is the main characteristic of a group…

Highmark Blue Cross Blue Shield is trying to assess the possibility of predicting good and bad days for people suffering with multiple sclerosis (MS) and help them to achieve a higher quality of life. The four-week pilot program enrolled almost 100 participants that wore a body sensor patch,…

In a study entitled “Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination” the authors report to have found a new protein, Del-1, that reduces the severity of multiple sclerosis disease in a mouse model of the disease. The…

Photo From University of Alberta The company behind FDA-approved multiple sclerosis drug AVONEX® (Interferon beta-1a), Biogen Idec, together with the government of the province of Alberta, has…

Drug manufacturers Teva Pharmaceutical Industries Ltd. and Active Biotech announced that they expanding the ongoing clinical research program for the study of laquinimod, a potential treatment for primary progressive multiple sclerosis (PPMS), as the companies are now initiating the ARPEGGIO trial. In addition, Teva has also announced…

Sanofi subsidiary and rare disease treatment specialist Genzyme has just announced the successful enrollment of the first participant in their multicenter Phase II clinical trial for the company’s pipeline intravenous drug for relapsing-remitting multiple sclerosis (RRMS), vatelizumab. This novel drug is composed of humanized monoclonal antibodies that specifically target…

The National Multiple Sclerosis Society recently awarded MS researcher Lauren Strober, PhD from the Kessler Foundation, a three-year grant for her investigational research, totaling $457,921. The funding is part of a multi-site study that will be conducted by the investigator to understand the influence that having…

A study entitled “Longitudinal Follow-up of a Cohort of Patients with Incidental Abnormal Magnetic Resonance Imaging Findings at Presentation and Their Risk of Developing Multiple Sclerosis” published in the International Journal of MS Care reports that asymptomatic patients accompanied by Magnetic Resonance Images suggestive of…

A study presented at the 61st annual meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) held October 29 to November 1 in Savannah, Georgia, further corroborates growing awareness of a high prevalence of vitamin D deficiency in neuromuscular disease.’ The study, entitled “…

An encouraging experimental drug that is being developed for Multiple Sclerosis continues to show promise in being able to offer neuroprotective benefits — an effect that could slow and eventually cure MS. Masitinib, which is being developed by AB Science for numerous neurological indications, including Alzheimer’s disease, progressive multiple sclerosis, and amyotrophic…

Researchers from UC San Francisco, the Broad Institute of MIT and Harvard, and Yale School of Medicine recently developed a software tool that helps researchers understand the complex genetic origins of many autoimmune diseases and, ultimately, to better diagnose and treat them. The study was published yesterday in …

Next Sunday, November 2nd, Sydney, Australia will hold one of the country’s largest fundraising events to support multiple sclerosis research and advocacy, the MS Gong Ride, a one day community bike ride designed to collect $3.8 million. Each biker is asked to help raise $250 for the historic ride that celebrates its…

The National Multiple Sclerosis Society granted the 2014 Barancik Prize for Innovation in MS Research to Philip Laurence De Jager, MD, PhD, who is a neurologist at Brigham and Women’s Hospital, as well as an associate professor of neurology at the Harvard Medical School. The award, meant to…

Among autoimmune diseases, Multiple Sclerosis is one of the most progressive and debilitating, affecting between 300,000 and 400,000 people in the United States alone. The cause of the disease remains elusive to researchers, making it extremely difficult to research and develop effective therapies for treating symptoms and reversing neural…

While Canada is home to one of the world’s most comprehensive social healthcare systems, it is unfortunately home to one of the largest multiple sclerosis patient populations as well. According to the Multiple Sclerosis Society of Canada, at least 100,000 Canadians have the disease, and at least 20,000 of them live…

The National Multiple Sclerosis Society‘s Lone Star Chapter, which is sponsoring the nonprofit organization’s annual Houston-area Walk MS fundraisers, has announced that Woodlands-based biopharmaceutical company Opexa Therapeutics, a company currently developing personalized immunotherapies for multiple sclerosis (MS), will also support the fundraising effort. This is the fourth consecutive…

A new study entitled, “Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases” published in the JAMA Neurology journal, reports that no association was observed between vaccinations and an increased risk for Multiple Sclerosis or other central nervous system…

The Consortium of Multiple Sclerosis Centers (CMSC) has announced that its next annual meeting will be held in 2015 between May 27 th and 30th at the JW Marriott Hotel in Indianapolis, Indiana. The 2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers aims to gather healthcare professionals as…

The first and largest study on the association between Multiple Sclerosis (MS) and Uveitis was recently presented at the 18th annual meeting of the American Academy of Ophthalmology. The meeting was held at the McCormick Place in Chicago between October 17-21, 2014. Uveitis is a disorder characterized by inflammation of…

Much of the research and development focus for treating Multiple Sclerosis revolves around pharmaceuticals. However, the development and use of novel medical devices are also becoming a factor in treating the disease as well. A new study entitled “A dorsiflexion assist orthosis reduces the physiological cost…

The U.S. Supreme Court deliberated on a request from Teva Pharmaceutical Industries Ltd. to preserve the patent of its multiple sclerosis drug Copaxone from generic competitors until September 2015. Recent reports indicate that the court gave the company a mixed opinion. The hearing occurred this…

Evotec AG, a German company specializing in the provision of drug discovery resources to biotech companies and learning institutions, announced that is going to begin three new research projects for the treatment of multiple sclerosis (MS), which will be supported by funds from the German Federal Ministry of Education…

Spanish-Filipino biopharmaceutical startup Ankar Pharma is working on a promising treatment for multiple sclerosis (MS). Dr. Ana Martinez, a professor and researcher at the Biological Research Center (CIB) of the Spanish National Council for Research (CSIC), explains that while there are several palliative treatments available on the market…

New Zealand-based Pharmaceutical Management Agency (PHARMAC) has approved the funding of new treatments for multiple sclerosis (MS), which are expected not only to reach more patients, but also be more effective in curtailing the disease’s progressive symptoms. The therapies currently funded are meant for the treatment of …

The National Multiple Sclerosis Society recently honored several admirable MS advocates and leaders during the annual NMSS Ambassadors Ball, held in Washington, D.C., to benefit local MS patients and research initiatives. The upscale black-tie evening brought together some of the most accomplished industry leaders and celebrities at the Georgetown Ritz…

A new study entitled “NAD+ protects against EAE by regulating CD4+ T-cell differentiation” published in October issue of Nature Communications reports that NAD+ can be a future therapeutic drug to treat Multiple Sclerosis. Multiple sclerosis (MS) is a type of autoimmune disease where the inner…